Pay in 4 interest-free payments of $6.18 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Below are the available bulk discount rates for each individual item when you purchase a certain amount I used to get cystic pimples and the scars would stay for months
If you have any other questions, dont hesitate to contact us
MEDVi is not affiliated with these manufacturers
Key Takeaways Retatrutide (LY3437943) is an investigational weight loss medication developed by Eli Lilly Triple-agonist mechanism: First drug to activate GLP-1, GIP, and glucagon receptors simultaneously Phase 2 results: Up to 24.2% weight loss at 48 weeks (approximately 58 lbs for a 240-lb person) Not FDA-approved: Currently in Phase 3 clinical trials, expected approval in 20272028 How it differs: Outperforms semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) in weight loss trials Access now: Clinical trials (free), compounding pharmacies, or research peptide vendors What Is Retatrutide
However, affordability is not determined by price aloneindividual metabolic response, treatment duration, and genetic peptide predispositions significantly influence true cost-effectiveness
US$ 24.66
US$ 22.47
US$ 23.43
US$ 23.74
US$ 21.51
